Jan, 2021 Pharma & Healthcare
Global Immune Checkpoint Inhibitors Market 2020 By Manufacturers, Regions, Type, Application And Forecast Till 2027
Category by- Pharma & Healthcare , No. of Pages - 150, Published By - Ameco Research
The global Immune Checkpoint Inhibitors market size is projected to reach US$ 36030 million by 2026, from US$ 14730 million in 2020, at a CAGR of 16.1% during 2021-2026.
The global Immune Checkpoint Inhibitors market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Immune Checkpoint Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Geographical Analysis:
Based on region, the global Immune Checkpoint Inhibitors market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players:
The major players that are operating in the global Immune Checkpoint Inhibitors market are
Bristol Myer Squibb
AstraZeneca
Merck & Co.
Roche / Genentech
Incyte Corporation
NewLink Genetics
ArGEN-X
Seattle Genetics
Pfizer
MacroGenics
Celldex Therapeutics
CureTech
Immutep
Innate Pharma
Sorrento Therapeutics
GlaxoSmithKline
GITR, Inc
Segment by Type
PD-1/PD-L1
CTLA-4
Segment by Application
Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Melanoma
Blood Cancer
Other
The global Immune Checkpoint Inhibitors market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Immune Checkpoint Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Geographical Analysis:
Based on region, the global Immune Checkpoint Inhibitors market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players:
The major players that are operating in the global Immune Checkpoint Inhibitors market are
Bristol Myer Squibb
AstraZeneca
Merck & Co.
Roche / Genentech
Incyte Corporation
NewLink Genetics
ArGEN-X
Seattle Genetics
Pfizer
MacroGenics
Celldex Therapeutics
CureTech
Immutep
Innate Pharma
Sorrento Therapeutics
GlaxoSmithKline
GITR, Inc
Segment by Type
PD-1/PD-L1
CTLA-4
Segment by Application
Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Melanoma
Blood Cancer
Other